

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

MB49

RRID:CVCL_7076

Type: Cell Line

Proper Citation

CLS Cat# 305240, RRID:CVCL_7076

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_7076

Proper Citation: CLS Cat# 305240, RRID:CVCL_7076

Description: Cell line MB49 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Male

Disease: Mouse bladder transitional cell carcinoma

Defining Citation: [PMID:107359](#), [PMID:19539312](#), [PMID:22559978](#), [PMID:29732388](#), [PMID:29784854](#), [PMID:30867744](#)

Comments: Karyotypic information: Has lost chromosome Y (PubMed=22559978).

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: MB49

Synonyms: MB-49

Cross References: BTO:BTO_0003562, AddexBio:C0002004/5005, CancerTools:153368, CLS:305240, Millipore:SCC148, Ubigene:YC-C104, Wikidata:Q54904112, Ximbio:153368

ID: CVCL_7076

Vendor: CLS

Catalog Number: 305240

Record Creation Time: 20250423T101215+0000

Record Last Update: 20260905T185126+0000

Ratings and Alerts

No rating or validation information has been found for MB49.

No alerts have been found for MB49.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 203 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wu J, et al. (2026) O-GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune Evasion in Bladder Cancer. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(37), e19955.

Chen Z, et al. (2026) Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma. *Cell reports. Medicine*, 7(4), 102712.

Huang Y, et al. (2026) MCUB Inhibits PRKN-Dependent Mitophagic Degradation of PD-L1 to Promote Immune Evasion in Bladder Cancer. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(5), e14764.

Taguchi S, et al. (2026) Induced pluripotent stem cell-derived dendritic cells potentiate the efficacy of interleukin-12-expressing oncolytic HSV-1. *Molecular therapy. Oncology*, 34(2), 201252.

Lao J, et al. (2026) Targeted Delivery of Indole-3-Pyruvic Acid Suppresses Macrophage Ferroptosis to Enhance CD8+ T Cell-Mediated Immunotherapy Response in Bladder Cancer. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e76319.

Hunt KS, et al. (2026) Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L-CD40 Pathway. *Cancer immunology research*, 14(7), 1068.

Marco S, et al. (2026) Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity. *Cancer cell*, 44(5), 995.

Luo W, et al. (2026) CCL5 hiCD4+ T Cells Regulate Macrophage Polarization and Promote Immunotherapy Response in Bladder Cancer. *Cancer research*, 86(9), 2202.

Zhong Z, et al. (2026) Engineered T cell membrane coated nanoparticles reverse thermo-resistance and reprogram tumor microenvironment to synergistically potentiate bladder cancer photothermal immunotherapy. *Journal of nanobiotechnology*, 24(1).

Xiong W, et al. (2025) Short-term high-dose gemcitabine induces PERK-mediated immunogenic cell death and potentiates antitumor immunity in bladder cancer. *International immunopharmacology*, 162, 115057.

Zhang J, et al. (2025) Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion. *Cancer research*, 85(18), 3435.

Song NJ, et al. (2025) Tumor-associated NK Cells Regulate Distinct CD8⁺ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers. *Cancer discovery*, 15(9), 1835.

Tong Y, et al. (2025) METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5/CCL5 regulation. *Journal for immunotherapy of cancer*, 13(4).

Wang X, et al. (2025) PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway. *Cancer discovery*, 15(3), 633.

Hatayama T, et al. (2025) Crucial Contribution of BACH1 to Bladder Cancer Progression via Upregulating Epithelial-Mesenchymal Transition Pathway. *Cancer science*.

Nelson KL, et al. (2025) VAX014 Activates Tumor-Intrinsic STING and RIG-I to Promote the Development of Antitumor Immunity. *Molecular cancer therapeutics*, 24(4), 587.

Li C, et al. (2025) Glutamate transporter SLC1A6 promotes resistance to immunotherapy in cancer. *Cancer immunology, immunotherapy : CII*, 74(8), 240.

Knorr DA, et al. (2024) Fc γ RIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. *Cancer immunology research*, 12(3), 322.

Prabagar MG, et al. (2024) THE STING AGONIST VB-85247 INDUCES DURABLE ANTITUMOR IMMUNE RESPONSES BY INTRAVESICAL ADMINISTRATION IN A NON-MUSCLE INVASIVE BLADDER CANCER. *Cancer research*.

Zhang L, et al. (2023) The m6A Reader YTHDF2 Promotes Bladder Cancer Progression by Suppressing RIG-I-Mediated Immune Response. *Cancer research*, 83(11), 1834.